MAY 03, 2018 1:48 AM PDT

Treating Migraines with Less Side-Effects

WRITTEN BY: Nouran Amin

According to a 2013 Global Burden of Disease Study and the World Health Organization (WHO), migraine makes the list as the sixth highest cause worldwide for years lost due to disability.

Now, scientists have stumbled upon a side-effect free treatment option for chronic migraines. These side-effects that are usually accompanied with conventional treatments include fatigue, racing heartbeat, or nausea.

The discovered drug is erenumab which works against migraines to inhibit pain signals by targeting a receptor for calcitonin gene-related peptide (CGRP). According to the American Academy of Neurology, CGRP is responsible for the pain trsamiiosn. With erenumab, the drug works to inhint the nerves to which CGRP peptide binds, ebentiaull blocking the pain.

To test the effectiveness of the drug, investigators examined 246 people who are considered “more difficult to treat” noted by study author Uwe Reuter in a news release. The participants received injections of either 140 milligrams of erenumab or a placebo once every month for a total of three months.

“Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief,” explains Uwe Reuter said, “More research is now needed to understand who is most likely to benefit from this new treatment.” However, one disadvantage from this study was that researchers evaluated patients over a three-month period.

Current treatment options for migraines include OTC counter NSAIDs or dedicated triptans. These treatment options come with their own side effects such as drowsiness, dizziness or slow-thinking. “There’s no current dedicated migraine prevention medication,” says Dr. Michael R. Silver, an assistant professor in neurology at Emory University. “We borrow from other fields and use mostly anti-seizure medicines, blood pressure medicines or anti-depressants for migraine prevention.”

However, erenumabs provide promising treatment. “We’ve known CGRP have been involved in migraines for years and now, we’re finally coming out with medicines to address what is likely the root cause of migraine pain.”

Although erenumab is currently up for approval by the FDA, one downside might be the cost of having this treatment. Regardless, Dr. Silver believes that “this will hopefully usher in the new era of migraine treatment”.

Sources: American Academy of Neurology

 

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUL 23, 2022
Drug Discovery & Development
No Evidence for Depression and Serotonin Activity Link
JUL 23, 2022
No Evidence for Depression and Serotonin Activity Link
A new review study found that there is no clear evidence that serotonin levels or serotonin activity are responsible for ...
SEP 07, 2022
Drug Discovery & Development
Perfusion Media Survey Panel: Overview From an Expert
SEP 07, 2022
Perfusion Media Survey Panel: Overview From an Expert
Achieving high cell densities in long-term cultures is often a challenge facing bioprocessing manufacturers, and one tha ...
SEP 07, 2022
Drug Discovery & Development
An Oral Insulin Pill is Getting Closer
SEP 07, 2022
An Oral Insulin Pill is Getting Closer
Diabetes is a chronic disease that requires constant monitoring. Patients have to check the level of sugar, or glucose i ...
OCT 05, 2022
Health & Medicine
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
OCT 05, 2022
Emergency Contraception Pills are Significantly Less Effective in People Who Are Overweight
Emergency contraception pills can be used to prevent pregnancy within 72 hours of having unprotected sex. When taken as ...
OCT 03, 2022
Clinical & Molecular DX
Could Blood Samples Detect the Risk of Peripheral Neuropathy in Type 2 Diabetes?
OCT 03, 2022
Could Blood Samples Detect the Risk of Peripheral Neuropathy in Type 2 Diabetes?
Type 2 diabetes is a disease that impacts the body’s ability to respond to insulin. Insulin is a hormone made by t ...
OCT 04, 2022
Cancer
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
OCT 04, 2022
The NCI Welcomes First Woman Director: Monica M. Bertagnolli, MD
In August, President Biden announced his intention to appoint Dr. Monica M. Bertagnolli as the newest director of the Na ...
Loading Comments...